Study: Low-dose HCQ and mortality rate in 8075 hospitalized Covid19 patients
sciencedirect.com
sciencedirect.com
These results seem well randomized with a sufficiently large sample. They come from a reputable European Belgian University (UGent) with nationwide data from 109 hospitals.
TLDR: "Of 8075 patients with complete discharge data on 24th of May and diagnosed before the 1st of May, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, the mortality was lower in the HCQ group compared to the no-HCQ group (adjusted hazard ratio [HR] 0.684, 95% confidence interval [CI] 0.617–0.758). Compared to the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤ 5 days (n=3975) and > 5 days (n=3487) after symptom onset (adjusted HR 0.701, 95% CI 0.617–0.796 and adjusted HR 0.647, 95% CI 0.525–0.797, respectively)."
Hydroxychloroquine's been shown effective repeatedly when it's started early. No reason not to try in patients for whom it's safe as a malaria prophylactic.